Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Published:2018-04-02 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Atallah Ehab,Schiffer Charles A.,Weinfurt Kevin P.,Zhang Mei-Jie,Radich Jerald P.,Oehler Vivian G.,Pinilla-Ibarz Javier,Deininger Michael W. N.,Lin Li,Larson Richard A.,Mauro Michael J.,Moore Joseph O.,Ritchie Ellen K.,Shah Neil P.,Silver Richard T.,Wadleigh Martha,Cortes Jorge,Thompson James,Guhl Jessica,Horowitz Mary M.,Flynn Kathryn E.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4273-1.pdf

Reference32 articles.

1. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–7.

2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.

3. Druker BJ, Fo G, O'Brien SG, et al. Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.